Post ASCO GU ’22 – Muscle-Invasive Bladder Cancer, EV-103, Enfortumab Vedotin, and the Clinical Progress Being Made Managing MIBC Patients

Daniel Petrylak, MD, Professor of Medicine at the Yale Cancer Center, and Robert Figlin, MD, of Cedars-Sinai Cancer discuss recent developments at ASCO GU in muscle-invasive bladder cancer and in particular the EV-103 clinical study while also discussing the future of MIBC treatment.